Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 5,610,659 shares at $21.68 ($121.6M) on 2025-12-15, disclosed to the SEC on 2025-12-17.
Seasonal sale ($121.6M) by CEO — this insider has traded ROIV in December in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.68 | 3,739 | $81K | 0.1% |
| 2 | $21.68 | 230,357 | $5.0M | 4.1% |
| 3 | $21.68 | 230,357 | $5.0M | 4.1% |
| 4 | $21.68 | 566,116 | $12.3M | 10.1% |
| 5 | $21.68 | 566,116 | $12.3M | 10.1% |
| 6 | $21.68 | 797,595 |
| $17.3M |
| 14.2% |
| 7 | $21.68 | 943,527 | $20.5M | 16.8% |
| 8 | $21.68 | 943,527 | $20.5M | 16.8% |
| 9 | $21.68 | 1,329,325 | $28.8M | 23.7% |
| Total | $21.68 avg | 5,610,659 | $121.6M | 100% |
| Filing → |
| ROIV | SELL | 2024-09-24 | $46.8M | — | Filing → |
| ROIV | SELL | 2022-10-27 | $170K | — | Filing → |
| ROIV | SELL | 2022-09-27 | $129K | — | Filing → |